drugset / Trial / NCT05426681
Spinal Cord Injury Neuroprotection With Glyburide
NaSingle-groupOpen-labelTreatment
Summary
To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.
Timeline
- Start
- 2022-07-07
- Primary completion
- 2027-05
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glyburide | Small molecule | 0.625 mg | Oral |